淺談強效降血脂藥：PCSK9抑制劑

A brief dissertation on the high-potency lipid-lowering agents: PCSK9 inhibitors

10.6647/CN.202303_30(1).0003

徐麗珍(Lih-Jen Shyu)

PCSK9抑制劑 ； Alirocumab ； Evolocumab ； 高血脂 ； PCSK9 inhibitors ； Alirocumab ； Evolocumab ； Hyperlipidemia

彰化護理

30卷1期（2023 / 03 / 01）

8 - 13

繁體中文;英文

PCSK9抑制劑（proprotein convertase subtilisin/kexin type 9 inhibitor）為運用基因重組技術製成的單株抗體，屬於強效降血脂藥，主要用於對statin療效不佳、有禁忌症或不耐受副作用的病人，可降低發生重大心血管事件的風險。雖然PCSK9抑制劑整體療效頗優，但具個體差異性；副作用發生率不高，但具免疫原性，目前影響未知；藥價昂貴、注射劑型使用不便，故臨床使用須定期監測療效與安全性以維護患者用藥安全。

PCSK9 inhibitors (proprotein convertase subtilisin/kexin type 9 inhibitors) are monoclonal antibodies made by genetic recombination technique, which are high-potency lipid-lowering agents. They are mainly used for patients on statin therapy with poor efficacy, contraindications or intolerance, and then reduce the risk of major cardiovascular events. Although PCSK9 inhibitors are quite efficacious as a whole, inter-individual variability existed. They possess low incidence of adverse events, however, another issue that raise concerns is the immunogenicity with unknown impact currently. Also, PCSK9 inhibitors are expensive and inconvenient administration cause of the injectable form. Therefore, monitoring for efficacy and safety regularly should be taken to stand up for the medication safety of patients on PCSK9 inhibitors therapy.

1. Guedeney, P.,Sorrentino, S.,Giustino, G.,Chapelle, C.,Laporte, S.,Claessen, B.E.,Ollier, E.,Camaj, A.,Kalkman, D.N.,Vogel, B.,Rosa, S.D.,Indolfi, C.,Lattuca, B.,Zeitouni, M.,Kerneis, M.,Silvain, J.,Collet, J.P.,Mehran, R.,Montalescot, G.(2021).Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis.European Heart Journal -Cardiovascular Pharmacotherapy,7(3),225-235.
2. Marina, B.R.,Laura, A.P.,Reyes, T.C.,María, J.A.S.,Antonio, A.P.,María, M.C.B.,Rodrigo, M.P.,Irene, P.O.,Belen, S.R.,Luis, A.Z.,Roberto, V.M.,Manuel, P.O.,Alba, M.C.F.,Cristina, D.T.P.,Pablo, G.B.,Eduardo, A.M.,Purificacion, S.L.,Beatriz, H.M.,Ricardo, R.C.,Patricia, M.S.(2021).Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRISPCSK9I study.Atherosclerosis Plus,45,32-38.
3. Oettgen, P. (2022). PCSK9 Inhibitors. DynaMed. Retrieved Jan. 18, 2023, form https://www.dynamed.com/drug-review/pcsk9-inhibitors
4. Rallidis, L. S.,Skoumas, I.,Liberopoulos, E. N.,Vlachopoulos, C.,Kiouri, E.,Koutagiar, I.,Anastasiou, G.,Kosmas, N.,Elisaf, M. S.,Tousoulis, D.,Iliodromitis, E.(2020).PCSK9 inhibitors in clinical practice: Novel directions and new experiences.Hellenic Journal of Cardiology,61(4),241-245.
5. Rosenson, R. S. (2022). Low-density lipoprotein cholesterol lowering with drugs other than statins and PCSK9 inhibitors. UpToDate. Retrieved Jan. 12, 2023, formhttps://www.uptodate.com/contents/low-density-lipoprotein-cholesterol-lowering-with-drugs-other-than-statins-and-pcsk9-inhibitors
6. Schmidt, A.F.,Carter, J.P.L.,Pearce, L.S.,Wilkins, J.T.,Overington, J.P.,Hingoranin, A.D.,Casas, J.P.(2020).PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.Cochrane Database of Systematic Reviews,10(10),CD011748.
7. Stroes, E. SG., Stiekema, L. CA., & Rosenson, R. S. (2022). PCSK9 inhibitors: Pharmacology, adverse effects, and use. UpToDate. Retrieved Jan. 12, 2023, form https://www.uptodate.com/contents/pcsk9-inhibitors-pharmacology-adverse-effects-and-use
8. 衛生福利部中央健康保險署(2023)．藥品給付規定。https://www.nhi.gov.tw/Content_List.aspx?n=E70D4F1BD029DC37&topn=3FC7D09599D25979